Opioid-Related Disorders Clinical Trial
— PRE-FAIROfficial title:
Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: FAIR
Young parents aged 16 to 30, involved in the DHS system for child welfare or self-sufficiency needs are at risk for opioid use disorder and/or methamphetamine use disorder (OUD; MUD). Those identified as engaging in opioid or methamphetamine misuse are at high risk for escalation. Children of parents with OUD and MUD are at-risk for entering into foster care. Oregon is one state particularly affected by this challenge. The proposed UG3/UH3 offers one potential solution by adapting and evaluating a recently developed treatment for parental OUD and MUD, for prevention. This study seeks to collaborate with Oregon Department of Humans Services (DHS) leadership to deliver a new outpatient prevention program to high-risk, young, parents. The Families Actively Improving Relationships (FAIR) program will include community-based mental health, parent management, and ancillary needs treatment, and ongoing monitoring and prevention services for opioid and methamphetamine use. This study will randomize 240 parents, aged 16 to 30, to receive FAIR or standard case management and referral, in two counties in Oregon. Outcomes will include an evaluation of the effectiveness of FAIR in addressing risk factors associated with substance use disorders in DHS-involved populations, OUD and MUD outcomes, and implementation outcomes including implementation process and milestones, and program delivery outcomes. Intervention and Implementation costs will be assessed, and the benefit of FAIR will be evaluated in relation to standard services, but also in relation to capacity and population needs. Study hypotheses are: (1) Parents randomized to FAIR will be less likely to escalate opioid and/or methamphetamine use, and to receive a diagnosis of OUD and/or MUD; (2) Parents randomized to FAIR will experience significant reductions in mental health, parent skills, and ancillary needs compared to those receiving standard services; (3) Counties will follow the implementation plan developed in collaboration between study team members and state leadership, and that doing so will yield successful implementation of FAIR; and (4) Implementation and intervention costs for FAIR will demonstrate a benefit for offering FAIR compared to standard services, particularly in rural communities where capacity influences service delivery decisions.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years to 30 Years |
Eligibility | Inclusion Criteria: 1. Risk for opioid or methamphetamine misuse or escalation of use 2. Parent of a child 0-18. 3. Involvement or risk for involvement with self-sufficiency or child welfare systems. 4. Aged 16 to 30 at date of intake assessment. 5. Enrolled in Oregon Health Plan 6. Child in home or reunification plan in place. 7. Lives in a participating Oregon county. Exclusion Criteria: - Greater than 3 uses of methamphetamine of opioids in the past year |
Country | Name | City | State |
---|---|---|---|
United States | OSLC | Eugene | Oregon |
Lead Sponsor | Collaborator |
---|---|
Chestnut Health Systems |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Changes in Drug Use Frequency and Severity from Baseline to 24-months Post-Baseline | Drug use frequency and severity measured through the Addiction Severity Index's (ASI) Drug Use subscale. Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline to 24-months Post-Baseline | |
Primary | Mean Changes in Mental Health Symptoms from Baseline to 24-months Post-Baseline | Mental health symptoms as measured by the Brief Symptom Inventory (BSI). Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline to 24-months Post-Baseline | |
Primary | Mean Changes From Baseline in Parenting Behaviors as Assessed by the BCAP at 24-months Post-Baseline | Parenting behaviors as measured by the Brief Child Abuse Potential Inventory (BCAP). Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline to 24-months Post-Baseline | |
Primary | Completion of Key Intervention Implementation Activities Over the Course of the Study | Measure of implementation progress as measured by the Stages of Implementation Completion (SIC). | Duration of the study, up to 4 years | |
Primary | Costs Associated with Key Intervention Implementation Activities Over the Course of the Study | Implementation costs associated with adoption of FAIR as measured by the Cost of Implementing New Strategies (COINS). | Duration of the study, up to 4 years | |
Primary | Mean changes in parent drug cravings and stress as measured by the Parent Daily Report | Parental stress and drug cravings as measured by the Parent Daily Report (PDR). Measured monthly from Baseline to 18-months post-Baseline and at 24-months post-Baseline. | Baseline, monthly for 18-months post-Baseline, 24-months post-Baseline | |
Primary | Mean changes in parenting stress as measured by Parenting Stress Inventory | Parenting stress as measured by the Parent Stress Inventory (PSI). Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline; 4-, 8-, 12-, 18-, and 24- months post Baseline | |
Primary | Mean changes in social and health related services used as assessed by the Service Utilization Survey | Social services and health related service use as measured by the Service Utilization Survey. Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline; 4-, 8-, 12-, 18-, and 24- months post Baseline | |
Primary | Mean changes in post-traumatic stress and psychological effects of trauma as measured by the Trauma Symptom Inventory-2 (TSI-2) | Measure of PTSD symptoms and psychological effects of trauma as measured by the Trauma Symptoms Inventory-2 (TSI-2). Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline; 4-, 8-, 12-, 18-, and 24- months post Baseline | |
Primary | Mean changes in drug use as measured by Urinalysis testing | Urinalysis based multi-drug panel using the ICUP Drug Screening device. Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline; 4-, 8-, 12-, 18-, and 24- months post Baseline | |
Primary | Mean changes in anxiety symptoms reported as measured by the General Anxiety Disorder-7 (GAD-7) | Anxiety symptoms as measured by the General Anxiety Disorder-7 (GAD-7). Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline; 4-, 8-, 12-, 18-, and 24- months post Baseline | |
Primary | Mean changes in depression severity as measured by the Patient Health Questionnaire-9 (PHQ-9) | Depression severity as measured by the Patient Health Questionnaire-9 (PHQ-9). Measured at Baseline, 4-, 8-, 12-, 18-, and 24-Months Post-Baseline. | Baseline; 4-, 8-, 12-, 18-, and 24- months post Baseline | |
Primary | Program Fidelity Ratings | Fidelity ratings of FAIR program fidelity as measured through behavioral coding of FAIR supervision sessions | Duration of study, up to 4 years | |
Secondary | Descriptive Measures of FAIR Program Delivery | Descriptives of FAIR program delivery including: fidelity, attendance, caseload size, case characteristics, and session characteristics will be collected. | Duration of the study, up to 4 years | |
Secondary | Mean Levels of Client Satisfaction with Services at the End of Treatment | Participants' self-reported perceptions of services as measured by the Client Satisfaction with Services Questionnaire (CSQ). | End of treatment, average of 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03950492 -
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
|
N/A | |
Completed |
NCT00000335 -
Activity Monitoring Assessment of Opiate Withdrawal - 4
|
Phase 2 | |
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
Completed |
NCT02978417 -
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
|
Phase 4 | |
Withdrawn |
NCT03137030 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03137017 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT00710385 -
Abuse Liability of Suboxone Versus Subutex
|
Phase 3 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Terminated |
NCT00000243 -
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
|
N/A | |
Completed |
NCT00067184 -
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
|
||
Completed |
NCT00000264 -
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
|
N/A | |
Completed |
NCT00000257 -
Effects of Alcohol History on Effects of Nitrous Oxide - 9
|
N/A | |
Completed |
NCT00000279 -
Novel Medications for Opiate Detoxification - 4
|
Phase 2 | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
Completed |
NCT00000249 -
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
|
Phase 2 | |
Recruiting |
NCT04933084 -
Pre-operative Education Modalities to Decrease Opioid Use
|
N/A | |
Recruiting |
NCT03610672 -
Mobile Intervention for Young Opioid Users
|
N/A |